fbpx

Study Shows CBD Reduces Joint Pain in Dogs

Researchers at Cornell University completed a pharmacokinetic study that suggests that cannabidiol (CBD) can relieve the symptoms of osteoarthritis in dogs.

The study was headed by Joseph Wakshlag, associate professor of Clinical Nutrition at Cornell University’s College of Veterinary Medicine. The team’s goal was to study the accuracy and frequency of dosing and assess the efficacy of CBD to manage pain in dogs.

The team worked with two different doses of CBD oil provided by ElleVet Sciences – 2 mg/kg and 8 mg/kg. They did not see adverse side effects for either dosage. However, serum chemistry showed that alkaline phosphatase activity increased.

The investigators tested CBD oil’s pain management properties using a randomized, placebo-controlled, double-blind study. They gave dogs either CBD oil or placebo oil every 12 hours. They treated the dogs for four weeks with a two-week washout period.

The owners of the dogs answered questionnaires and veterinarians conducted assessments before treatment and at weeks two and four. These included physical exams, hematology, and serum chemistry.

The team analyzed the Canine Brief Pain Inventory score and Hudson activity score to determine the response to the treatment. The Hudson activity score is a visual analog scale questionnaire used to assess pain and lameness in dogs.

The study suggests that 2 mg/kg of CBD twice daily can help increase comfort and activity in dogs with osteoarthritis. The Canine Brief Pain Inventory and Hudson activity scores showed a clinically significant reduction in pain and an increase in activity with CBD treatment.

According to Dr. Wakshlag, his team is also working on a pharmacokinetic and safety study on cats. They plan to conduct additional studies on the efficacy of CBD oil to treat a number of problems.

CBD products for pets are already available in the market. They are available in the form of oils, edibles, tinctures, and capsules. Most companies use hemp-derived CBD, which contains less than 0.3% of THC, so these products have no psychoactive effect.

CBD treatments are gaining popularity due to their efficacy. The same goes for the CBD market as a whole. The Hemp Business Journal estimated that the CBD market would grow to $2.1 billion in consumer sales by 2020. They expect $450 million of these sales to come from hemp-derived CBD.

 

Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’